Study Evaluating Prevenar in High-Risk Children

NCT00234338

Last updated date
Study Location
Frankfurt, , 60590, Germany
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-5 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- High-risk children ages 2 to 5 years old

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior administration of Prevenar


- Prior and/or concurrent administration of 23 vPs vaccine

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Edegem,
  2. Jindrichuv Hradec,
  3. Jindrichuv Hradec,
  4. Jindrichuv Hradec,
  5. Pardubice,
  6. Praha 3,
  7. Sezemice,
  8. Helsinki,
  9. Kokkola,
  10. Tampere,
  11. Espoo,
  12. Järvenpää,
  13. Oulu,
  14. Pori,
  15. Seinajoki,
  16. Turku,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Fukuoka-City, Fukuoka
  2. Akashi-City, Hyōgo
  3. Kumamoto-shi, Kumamoto
  4. Setagaya-ku, Tokyo
  5. Shinjuku-ku, Tokyo
  6. Suginami-ku, Tokyo
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Walnut Creek, California
  2. Miami, Florida
  3. Meridian, Idaho
  4. Saint Louis, Missouri
  5. Binghamton, New York
  6. Mobile, Alabama
  7. Chandler, Arizona
  8. Phoenix, Arizona
  9. San Diego, California
  10. Coral Gables, Florida
  11. Crystal River, Florida
  12. Hialeah, Florida
  13. Miami, Florida
  14. El Dorado, Kansas
  15. Wichita, Kansas
  16. Wichita, Kansas
  17. New Orleans, Louisiana
  18. Elkridge, Maryland
  19. Rockville, Maryland
  20. Omaha, Nebraska
  21. Las Vegas, Nevada
  22. Las Vegas, Nevada
  23. Charlotte, North Carolina
  24. Greensboro, North Carolina
  25. Hickory, North Carolina
  26. Raleigh, North Carolina
  27. Raleigh, North Carolina
  28. Wilmington, North Carolina
  29. Fargo, North Dakota
  30. Cincinnati, Ohio
  31. Cincinnati, Ohio
  32. Cleveland, Ohio
  33. Franklin, Ohio
  34. Warwick, Rhode Island
  35. Little River, South Carolina
  36. Mount Pleasant, South Carolina
  37. Bristol, Tennessee
  38. Nashville, Tennessee
  39. Austin, Texas
  40. Fort Worth, Texas
  41. Fort Worth, Texas
  42. Houston, Texas
  43. McKinney, Texas
  44. Pearland, Texas
  45. San Antonio, Texas
  46. Tomball, Texas
  47. Tomball, Texas
  48. Draper, Utah
  49. Salt Lake City, Utah
  50. Salt Lake City, Utah
  51. South Jordan, Utah
  52. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
  1. College Park, Georgia
  2. Jackson Heights, New York
  3. Beaumont, Texas
  4. Beaumont, Texas
  5. McAllen, Texas
  6. Cullman, Alabama
  7. Dothan, Alabama
  8. Phoenix, Arizona
  9. Fayetteville, Arkansas
  10. Bell Gardens, California
  11. Bellflower, California
  12. Covina, California
  13. Gardena, California
  14. Hawthorne, California
  15. Los Angeles, California
  16. Ontario, California
  17. Paramount, California
  18. Valencia, California
  19. West Covina, California
  20. Colorado Springs, Colorado
  21. Apopka, Florida
  22. Boynton Beach, Florida
  23. Gainesville, Florida
  24. Gainesville, Florida
  25. Hialeah, Florida
  26. Homestead, Florida
  27. Loxahatchee Groves, Florida
  28. Miami Lakes, Florida
  29. Miami, Florida
  30. Miami, Florida
  31. Tampa, Florida
  32. Chamblee, Georgia
  33. Columbus, Georgia
  34. Columbus, Georgia
  35. Ammon, Idaho
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Idaho Falls, Idaho
  39. Idaho Falls, Idaho
  40. Idaho Falls, Idaho
  41. Nampa, Idaho
  42. Ankeny, Iowa
  43. Des Moines, Iowa
  44. Des Moines, Iowa
  45. West Des Moines, Iowa
  46. El Dorado, Kansas
  47. Bardstown, Kentucky
  48. Louisville, Kentucky
  49. Baton Rouge, Louisiana
  50. Covington, Louisiana
  51. Haughton, Louisiana
  52. Metairie, Louisiana
  53. Baltimore, Maryland
  54. Frederick, Maryland
  55. Gulfport, Mississippi
  56. Missoula, Montana
  57. Lincoln, Nebraska
  58. Lincoln, Nebraska
  59. Albuquerque, New Mexico
  60. East Setauket, New York
  61. East Setauket, New York
  62. East Syracuse, New York
  63. Liverpool, New York
  64. Stony Brook, New York
  65. Stony Brook, New York
  66. Dayton, Ohio
  67. Dayton, Ohio
  68. Fairfield, Ohio
  69. South Euclid, Ohio
  70. East Norriton, Pennsylvania
  71. Erie, Pennsylvania
  72. Fort Washington, Pennsylvania
  73. Charleston, South Carolina
  74. Cheraw, South Carolina
  75. North Charleston, South Carolina
  76. Bristol, Tennessee
  77. Clarksville, Tennessee
  78. Kingsport, Tennessee
  79. Corpus Christi, Texas
  80. Houston, Texas
  81. Houston, Texas
  82. Longview, Texas
  83. McAllen, Texas
  84. San Antonio, Texas
  85. Kaysville, Utah
  86. Layton, Utah
  87. Murray, Utah
  88. Roy, Utah
  89. Saint George, Utah
  90. Syracuse, Utah
  91. Charlottesville, Virginia
  92. Charlottesville, Virginia
  93. Vancouver, Washington
  94. Guayama,
  95. Trujillo Alto,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Study Evaluating Prevenar in High-Risk Children
Official Title Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years
Brief Summary The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Pneumococcal Disease
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Estimated Enrollment
 (submitted: October 5, 2005)
5000
Original Enrollment Same as current
Actual Study Completion Date April 2007
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • High-risk children ages 2 to 5 years old

Exclusion criteria:

  • Prior administration of Prevenar
  • Prior and/or concurrent administration of 23 vPs vaccine
Sex/Gender
Sexes Eligible for Study:All
Ages 2 Years to 5 Years   (Child)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Germany
Removed Location Countries  
 
Administrative Information
NCT Number NCT00234338
Other Study ID Numbers 101850
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator:Trial ManagerFor Germany, [email protected]
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007